ArticleFrontiers in immunology2025

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines.

Cynthia González Muñoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.